子痫前期并发胎儿生长受限预测研究进展
Research Progress on the Prediction of Preeclampsia with Fetal Growth Restriction
DOI: 10.12677/ACM.2022.123336, PDF,   
作者: 刘 意:重庆医科大学第一临床医学院,重庆;重庆市垫江县人民医院,重庆;何佳佳*:重庆市垫江县人民医院,重庆
关键词: 子痫前期胎儿生长受限预测总结Preeclampsia Fetal Growth Restriction Prediction Summary
摘要: 子痫前期(PE)和胎儿生长受限(FGR)是产科孕产妇严重并发症,造成了严重的妊娠不良结局,早产、死产以及新生儿长期预后不良等。临床上对于先兆子痫伴发胎儿生长受限的诊断非常困难,导致了PE并发FGR的漏诊,能够早期预测诊断,及早进行临床干预是减少妊娠期不良结局的重要手段。传统的产检手段难以预测子痫前期和胎儿生长受限,国内外对于PE并发FGR的预测手段的研究也很多,出现了很多新的检测手段对预测PE伴发FGR有价值。本文是对PE伴发FGR的检测指标的回顾与分析。
Abstract: Preeclampsia (PE) and fetal growth restriction (FGR) are serious obstetric and maternal complications, resulting in severe adverse pregnancy outcomes, premature delivery, stillbirth and poor long-term prognosis of newborns. Clinical diagnosis of preeclampsia with fetal growth restriction is very difficult, leading to the missed diagnosis of PE complicated with FGR. Early diagnosis and early clinical intervention is an important means to reduce adverse outcomes in pregnancy. Traditional prenatal detection methods are difficult to predict preeclampsia and fetal growth restriction. There are many studies on the prediction methods of PE complicated with FGR at home and abroad, and many new detection methods are valuable to predict PE complicated with FGR. This paper reviewed and analyzed the detection indexes of PE complicated with FGR.
文章引用:刘意, 何佳佳. 子痫前期并发胎儿生长受限预测研究进展[J]. 临床医学进展, 2022, 12(3): 2334-2340. https://doi.org/10.12677/ACM.2022.123336

参考文献

[1] 段涛, 杨慧霞, 胡娅莉, 漆洪波, 孙路明, 郑明明. 胎儿生长受限专家共识(2019版) [J]. 中国产前诊断杂志(电子版), 2019, 11(4): 78-98.
[2] Kehl, S., Dotsch, J., Hecher, K., Schlembach, D., Schmitz, D., Stepan, H., et al. (2017) Intrauterine Growth Restriction. Guide-Line of the German Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry No. 015/080, October 2016). Geburtshilfe Frauenheilkd, 77, 1157-1173. [Google Scholar] [CrossRef] [PubMed]
[3] Ray, J.G., Vermeulen, M.J., Schull, M.J. and Redelmeier, D.A. (2005) Cardiovascular Health after Maternal Placental Syndromes (CHAMPS): Population-Based Retrospective Cohort Study. Lancet, 366, 1797-1803. [Google Scholar] [CrossRef
[4] Barker, D.J. (2006) Adult Consequences of Fetal Growth Restriction. Clinical Obstetrics and Gynecology, 49, 270-283.
[5] Jain, V. (2015) Letter to the Editor: Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy: Executive Summary. Journal d’obstétrique et gynécologie du Canada, 37, 774-775. [Google Scholar] [CrossRef
[6] Nuriyeva, G., Kose, S., Tuna, G., Kant, M., Akis, M., Altunyurt, S., et al. (2017) A Prospective Study on First Trimester Prediction of Ischemic Placental Diseases. Prenatal Diagnosis, 37, 341-349. [Google Scholar] [CrossRef] [PubMed]
[7] Zhong, Y., Zhu, F. and Ding, Y. (2015) Serum Screening in fiRst Trimester to Predict Pre-Eclampsia, Small for Gestational Age and Preterm Delivery: Systematic Review and Meta-Analysis. BMC Pregnancy Childbirth, 15, Article No. 191. [Google Scholar] [CrossRef] [PubMed]
[8] Conde-Agudelo, A., Papageorghiou, A., Kennedy, S. and Villar, J. (2013) Novel Biomarkers for Predicting Intrauterine Growth Restriction: A Systematic Review and Meta-Analysis. BJOG, 120, 681-694. [Google Scholar] [CrossRef] [PubMed]
[9] Espinoza, J., Romero, R., Nien, J.K., Gomez, R., Kusanovic, J.P., Gonçalves, L.F., et al. (2007) Identification of Patients at Risk for Early Onset and/or Severe Preeclampsia with the Use of Uterineartery Doppler Velocimetry and Placental Growth Factor. American Journal of Obstetrics & Gynecology, 196, 326.e321-326.e313. [Google Scholar] [CrossRef] [PubMed]
[10] Benton, S.J., Mccowan, L.M., Heazell, A.E., Grynspan, D., Hutcheon, J.A., Senger, C., et al. (2016) Placental Growth Factor as a Marker of Fetal Growth Restriction Caused by Placental Dysfunction. Placenta, 42, 1-8. [Google Scholar] [CrossRef] [PubMed]
[11] Villa, P.M., Hämäläinen, E., Mäki, A., Räikkönen, K., Pesonen, A.K., Taipale, P., et al. (2013) Vasoactive Agents for the Prediction of Early- and Late-Onset Preeclampsia in a High-Risk Cohort. BMC Pregnancy Childbirth, 13, Article No. 110. [Google Scholar] [CrossRef] [PubMed]
[12] Visan, V., Scripcariu, I.S., Socolov, D., Costescu, A., Rusu, D., Socolov, R., et al. (2019) Better Prediction for FGR (Fetal Growth Restriction) with the sFlt-1/PIGF Ratio: A Case-Control Study. Medicine, 98, e16069.
[13] Lawrence, J.B., Oxvig, C., Overgaard, M.T., et al. (1999) The Insulin-Like Growthfactor (IGF)-Dependent IGF Binding Protein-4 Protease Secreted Byhuman Fibroblasts Is Pregnancy-Associated Plasma Protein-A. Proceedings of the National Academy of Sciences of the United States of America, 96, 3149-3153. [Google Scholar] [CrossRef] [PubMed]
[14] Tong, S., Kaitu'u-Lino, T.J., Walker, S.P. and MacDonald, T.M. (2019) Blood-Based Biomarkers in the Maternal Circulation Associated with Fetal Growth Restriction. Prenatal Diagnosis, 39, 947-949. [Google Scholar] [CrossRef] [PubMed]
[15] Duan, H., Zhao, G., Xu, B., Hu, S. and Li, J. (2017) Maternal Serum PLGF, PAPPA, Beta-hCG and AFP Levels in Early Second Trimester as Predictors of Preeclampsia. Clinical Laboratory, 63, 921-925. [Google Scholar] [CrossRef
[16] 彭继文, 李佩佩, 徐怡然, 诸珍珍, 叶玲丽. 孕早期PAPP-A、β-HCG、Hcy等多参数综合评估胎儿生长受限的价值[J]. 生殖医学杂志, 2020, 29(11): 1477-1482.
[17] Karagiannis, G., Akolekar, R., Sarquis, R., Wright, D. and Nicolaides, K.H. (2011) Prediction of Small-for-Gestation Neonates from Biophysical and Biochemical Markers at 11-13 Weeks. Fetal Diagnosis and Therapy, 29, 148-154. [Google Scholar] [CrossRef] [PubMed]
[18] Dugoff, L., Hobbins, J.C, Malone, F.D., Porter, T.F., Luthy, D., Comstock, C.H., et al. (2004) First-Trimester Maternal Serum PAPP-A and Free-Beta Subunit Human Chorionic Gonadotropin Concentrations and Nuchal Translucency Are Associated with Obstetric Complications: A Population-Based Screening Study (The FASTER Trial). The American Journal of Obstetrics and Gynecology, 191, 1446-1451. [Google Scholar] [CrossRef] [PubMed]
[19] Taher, S.I., and Alalaf, S.K. (2019) Association between Serum Beta-Human Chorionic Gonadotropin and Preeclampsia and Its Effects on Perinatal and Maternal Outcomes: A Case Control Study. Archives of Gynecology and Obstetrics, 299, 713-718. [Google Scholar] [CrossRef] [PubMed]
[20] Sharony, R., Sharon-Weiner, M., Kidron, D., Sukenik-Halevy, R., Biron-Shental, T., Manor, M., et al. (2018) The Association between Maternal Serum First Trimester Free BetahCG, Second Trimester Intact hCG Levels and Foetal Growth Restriction and Preeclampsia. Journal of Obstetrics and Gynaecology, 38, 363-366. [Google Scholar] [CrossRef] [PubMed]
[21] 苗治晶, 乌兰. 血小板功能在胎儿生长受限患者的变化及诊断效能研究[J]. 实用妇科内分泌电子杂志, 2019, 6(34): 6-8.
[22] Briana, D.D. and Malamitsi-Puchner, A. (2021) Intrauterine Growth Restriction: The Controversial Role of Perinatal Adipocytokines in the Prediction of Metabolic Adult Disease. The Journal of Maternal-Fetal & Neonatal Medicine, 34, 2577-2582. [Google Scholar] [CrossRef] [PubMed]
[23] Kaitu’u-Lino, T.J., Tong, S., Walker, S.P., MacDonald, T.M., Cannon, P., Nguyen, T.V., et al. (2021) Maternal Circulating SPINT1 Is Reduced in Small-for-Gestational Age Pregnancies at 26 Weeks: Growing up in Singapore towards Health Outcomes (GUSTO) Cohort Study. Placenta, 110, 24-28. [Google Scholar] [CrossRef] [PubMed]
[24] 黄玉莲, 罗晓华, 谷存华, 郭晓珮. PS、PC和AT-III在胎儿生长受限中的诊疗价值[J]. 中外医学研究, 2021, 19(2): 71-73.
[25] Xu, C., Guo, Z., Zhang, J., Lu, Q., Tian, Q., Liu, S., et al. (2021) Non-Invasive Prediction of Fetal Growth Restriction by Whole-Genome Promoter Profiling of Maternal Plasma DNA: A Nested Case-Control Study. BJOG, 128, 458-466. [Google Scholar] [CrossRef] [PubMed]
[26] Hromadnikova, I., Dvorakova, L., Kotlabova, K. and Krofta, L. (2019) The Prediction of Gestational Hypertension, Preeclampsia and Fetal Growth Restriction via the First Trimester Screening of Plasma Exosomal C19MC microRNAs. International Journal of Molecular Sciences, 20, Article No. 2972. [Google Scholar] [CrossRef] [PubMed]
[27] Skalis, G., Katsi, V., Miliou, A., Georgiopoulos, G., Papazachou, O., Vamvakou, G., Nihoyannopoulos, P., Tousoulis, D. and Makris, T. (2019) MicroRNAs in Preeclampsia. Microrna, 8, 28-35. [Google Scholar] [CrossRef] [PubMed]
[28] ten Dijke, P., Goumans, M.J. and Pardali, E. (2008) Endoglin in Angiogenesis and Vascular Diseases. Angiogenesis, 11, 79-89. [Google Scholar] [CrossRef] [PubMed]
[29] Oujo, B., Perez-Barriocanal, F., Bernabeu, C. and Lopez-Novoa, J.M. (2013) Membrane and Soluble forms of Endoglin in Preeclampsia. Current Molecular Medicine, 13, 1345-1357. [Google Scholar] [CrossRef] [PubMed]
[30] Nogueira Reis, Z.S., Pereira, J.B., Costa, L.A.C. and Barra, J.S. (2020) Soluble Endoglin in Urine as an Early-Pregnancy Preeclampsia Marker: Antenatal Longitudinal Feasibility Study. Journal of Obstetrics and Gynaecology, 19, 693-698.
[31] Margioula-Siarkou, G., Margioula-Siarkou, C., Petousis, S., Margaritis, K., Alexandratou, M., Dinas, K., Sotiriadis, A. and Mavromatidis, G. (2021) Soluble Endoglin Concentration in Maternal Blood as a Diagnostic Biomarker of Preeclampsia: A Systematic Review and Meta-Analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology, 258, 366-381. [Google Scholar] [CrossRef] [PubMed]
[32] Zhao, W., Qiao, J., Zhang, Q., Zhao, Y. and Chen, Q. (2010) Levels of Antiangiogenic Factors in Preeclamptic Pregnancies. Growth Factors, 28, 293-298. [Google Scholar] [CrossRef] [PubMed]
[33] Singh, T., Leslie, K., Bhide, A., D’Antonio, F. and Thilaganathan, B. (2012) Role of Second-Trimester Uterine Artery Doppler in Assessing Stillbirth Risk. Obstetrics & Gynecology, 119, 256-261. [Google Scholar] [CrossRef
[34] Lakshmy, S.R., Praveenkumar, M., Shobana, U. and Thasleem, Z. (2017) Uterine Artery Doppler: Changing Concepts in Prediction and Prevention of PE and FGR. Journal of Fetal Medicine, 5, 93-105. [Google Scholar] [CrossRef
[35] 张利琴. 妊娠晚期母体子宫动脉和胎儿脐动脉血流参数预测胎儿生长受限及评估胎儿预后的价值[J]. 中国妇幼保健, 2021, 36(10): 2425-2428.
[36] 李宁, 李安洋, 赵亚东, 余亮. 孕晚期胎儿脐动脉、大脑中动脉及子宫动脉血流参数对FGR的诊断价值[J]. 皖南医学院学报, 2021, 40(1): 72-75.
[37] Adekanmi, A.J., Roberts, A., Akinmoladun, J.A. and Adeyinka, A.O. (2019) Uterine and Umbilical Artery Doppler in Women with Pre-Eclampsia and Their Pregnancy Outcomes. Nigerian Postgraduate Medical Journal, 26, 106-112. [Google Scholar] [CrossRef] [PubMed]
[38] 钟素霞. 超声多普勒检测UA及MCA血流参数预测胎儿FGR [J]. 吉林医学, 2014, 35(14): 3002-3003.
[39] Ozeren, M., Dinç, H., Ekmen, U., Senekayli, C. and Aydemir, V. (1999) Umbilical and Middle Cerebral Artery Doppler Indices in Patients with Preeclampsia. European Journal of Obstetrics & Gynecology and Reproductive Biology, 82, 11-16. [Google Scholar] [CrossRef
[40] Khalil, A., Morales-Rosello, J., Khan, N., Nath, M., Agarwal, P., Bhide, A., Papageorghiou, A., et al. (2017) Is Cerebroplacental Ratio a Marker of Impaired Fetal Growth Velocity and Adverse Pregnancy Outcome? American Journal of Obstetrics and Gynecology, 216, 606.e1-606.e10. [Google Scholar] [CrossRef] [PubMed]
[41] Novac, M.V., Moldoveanu, A., Tudorache, Ş., Oprescu, N.D., Miescu, M., Siminel, M.A., Vrabie, S., Novac, M.B. and Iliescu, D.G. (2017) Utility of Cerebroplacental Ratio in IUGR Fetuses from Pregnancy with Preeclampsia in Prediction the Risk for Perinatal Complications. Current Health Sciences Journal, 43, 231-235.
[42] 韩磊, 高燕华, 王珍芳, 彭建美, 韦爱华, 管湘平. 三维能量多普勒超声对晚孕期胎盘植入的诊断价值[J]. 临床与病理杂志, 2016, 36(10): 1616-1619.
[43] Yakovenko, K., Tamm, T. and Yakovenko, Y. (2018) A Study of U-Terine Hemodynamics Using Three-Dimensional Power Doppler Sonography in Patients with Adenomyosis. Georgian Med News, 5, 21-27.
[44] 李娟, 张颍, 翟莉丽, 王倩, 钱同刚, 冯晓明. 四维能量多普勒超声在胎儿生长受限预测中的可行性分析[J]. 中国煤炭工业医学杂志, 2021, 24(2): 132-136.